In this Issue
- As Trump Takes Office, Impact on Psychedelics Field Remains Unclear
- Psychedelics Advocate Sergey Brin Bags Seat in Billionaire’s Gallery
- When MAHA?
- NIH Freeze Stokes Funding Fears; Might Psychedelics Benefit?
- Psychedelic Power Couple, the Jurvetsons, Talk Trump, Lykos, and Philanthropy at Munich Conference
- Genevieve Jurvetson Hopes to Get MDMA Approved This Year
- J&J Buys Intra-Cellular for $14.6 Billion
- Lykos Provides Update on Board Departures, FDA Meeting, and U.S. Patent Applications
- GH Research Shares Positive Results from Proof of Concept Studies; Provides Update on FDA Clinical Hold
- and more…
***
As Trump Takes Office, Impact on Psychedelics Field Remains Unclear
Psychedelics Advocate Sergey Brin Bags Seat in Billionaire’s Gallery
Google co-founder Sergey Brin was given a prominent spot on the seating arrangement for Trump’s inauguration on Monday. He was sat among fellow billionaires and tech execs, perched beside Apple CEO Tim Cook.
While the view of Brin was often obscured by Trump’s towering son, Barron, viewers could see him join in with various standing ovations, such as when the incoming president announced that he was declaring a national emergency at the southern border and his “Drill, Baby, Drill!” proclamation1.
With execs lining up to kiss the ring, presumably in exchange for shelter from Trump’s slew of tariffs or some other benefit, it’s unclear why Brin is in Trump’s orbit or what he might be hoping to achieve. If Musk is after a contract to take us to Mars via SpaceX, is Sergey hoping to take us on an oneiric voyage via Soneira’s ibogaine?
Brin is, of course, no stranger to psychedelics, having been a long-time Burning Man attendee, often alongside his Google co-founder Larry Page. More recently, he ploughed $15 million into an ibogaine drug development startup Soneira Bio, which appears to be leveraging the work of Stanford researcher Nolan Williams—who is rumoured to be under consideration for a position in the second Trump administration.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
